130 related articles for article (PubMed ID: 27489049)
1. Efficacy and safety of doublet versus single agent as salvage treatment for metastatic breast cancer pretreated with anthracyclines and taxanes: a systematic review and meta-analysis.
Zhang T; Wang R; Liu Y; Huang J; Yang Z
Curr Med Res Opin; 2016 Nov; 32(11):1883-1889. PubMed ID: 27489049
[TBL] [Abstract][Full Text] [Related]
2. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
[TBL] [Abstract][Full Text] [Related]
3. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
5. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
Raggi D; Miceli R; Sonpavde G; Giannatempo P; Mariani L; Galsky MD; Bellmunt J; Necchi A
Ann Oncol; 2016 Jan; 27(1):49-61. PubMed ID: 26487582
[TBL] [Abstract][Full Text] [Related]
6. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
7. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
[TBL] [Abstract][Full Text] [Related]
8. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes.
Kalbakis K; Kouroussis C; Kakolyris S; Mavroudis D; Souglakos J; Agelaki S; Vamvakas L; Christodoulakis M; Stylianou K; Georgoulias V
Br J Cancer; 2001 Sep; 85(6):798-802. PubMed ID: 11556827
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.
Xu L; Wu X; Hu C; Zhang Z; Zhang L; Liang S; Xu Y; Zhang F
Onco Targets Ther; 2016; 9():4061-74. PubMed ID: 27445497
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Yamamoto D; Sato N; Rai Y; Yamamoto Y; Saito M; Iwata H; Masuda N; Oura S; Watanabe J; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Feb; 161(3):473-482. PubMed ID: 28005247
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
Petrelli F; Di Cosimo S; Lonati V; Barni S
Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
Roché H; Conte P; Perez EA; Sparano JA; Xu B; Jassem J; Peck R; Kelleher T; Hortobagyi GN
Breast Cancer Res Treat; 2011 Feb; 125(3):755-65. PubMed ID: 21128114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
